| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8228942 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 10 Pages | 
Abstract
												Adjuvant ADT results in a significant improvement in clinical progression and PCSM across multiple definitions of high-risk disease even with dose-escalated EBRT. There is a subset of patients, characterized by multiple high-risk features or the presence of Gleason Pattern 5, who remain at significant risk for metastasis and PCSM despite current treatment.
											Related Topics
												
													Physical Sciences and Engineering
													Physics and Astronomy
													Radiation
												
											Authors
												Matthew H. M.D., Kevin B.S., Schuyler B.S., Howard M. M.D., Felix Y. M.D., Daniel A. M.D., Ph.D., 
											